News Detail

New Delhi, 24 March 2023: The Indian Patent Office on Thursday rejected US pharmaceutical firm Johnson & Johnson’s (J&J) attempt to extend its monopoly in India on the TB drug bedaquiline beyond the primary patent’s expiry this July, according to people famili......
View Details
Source : Livemint
TB
J&J
Bedaquiline
TB medicine
primary patent’s expiry
Related News
- US FDA approves at-home artificial insemination kit for first time (07-12-2023)
- KMCH Transfusion Center activates MM Assay for safe transfusions (07-12-2023)
- 1140 Bottles of banned intoxicant cough syrup seized by Gharghoda Police, one arrested (07-12-2023)
- New drug law to be introduced in Parliament (07-12-2023)
- 67,000 patients became addicted to Buprenorphine in Punjab (07-12-2023)
- Stevia can't be used in cocoa & chocolate products and imitation chocolate: FSSAI (07-12-2023)
- Gujarat: Death Toll reaches seven in Kheda, Mumbai supplier arrested, Supplied 13,000 Litres of base solvent (07-12-2023)
- One arrested with 16 Buprenorphine Injs in Panipat and another with 28 Injs at Ambala (07-12-2023)
- 20,000 Yaba Tablets seized in Tripura near Bangladesh border by Assam Rifles (07-12-2023)
- NCH notifies regulations for medical research in Homoeopathy (07-12-2023)